BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 16897970)

  • 21. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
    Fukushima M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [5-fluorouracil and dihydropyrimidine dehydrogenase].
    Kubota T
    Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral DPD-inhibitory fluoropyrimidine drugs.
    Diasio RB
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):19-23. PubMed ID: 11098485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
    Cao S; Baccanari DP; Joyner SS; Davis ST; Rustum YM; Spector T
    Cancer Res; 1995 Dec; 55(24):6227-30. PubMed ID: 8521418
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmacokinetics of 5-FU after S-1 oral administration for adjuvant chemotherapy in gastric cancer patients].
    Matsumoto H; Hirai T; Hirabayashi Y; Murakami H; Higashida M; Kawabe Y; Fuchimoto M; Fujikura H; Hato S; Urakami A; Yamashita K; Tsunoda T
    Gan To Kagaku Ryoho; 2007 Jun; 34(6):869-73. PubMed ID: 17565248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats.
    Yoshisue K; Kanie S; Nishimura T; Chikamoto J; Nagayama S
    J Pharm Pharmacol; 2009 Dec; 61(12):1643-51. PubMed ID: 19958587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil.
    Saif MW; Rosen LS; Saito K; Zergebel C; Ravage-Mass L; Mendelson DS
    Anticancer Res; 2011 Feb; 31(2):625-32. PubMed ID: 21378348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts.
    Sakurai Y; Yoshida I; Kamoshida S; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
    Ann Surg Oncol; 2008 Aug; 15(8):2301-9. PubMed ID: 18506536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.
    Keith B; Guo XD; Zentko S; Harold N; Schuler B; Quinn M; Shapiro J; Grem JL
    Clin Cancer Res; 2002 May; 8(5):1045-50. PubMed ID: 12006517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of 5-FU plasma concentration by 13C breath test in patients treated with oral 5-FU analogs.
    Higashida M; Matsumoto H; Kubota H; Murakami H; Kawabe Y; Nakashima H; Oka Y; Okumura H; Nakamura M; Hirai T
    Anticancer Res; 2012 Dec; 32(12):5407-14. PubMed ID: 23225444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.
    Adjei AA; Reid JM; Diasio RB; Sloan JA; Smith DA; Rubin J; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Atherton P; Ames MM; Erlichman C
    J Clin Oncol; 2002 Mar; 20(6):1683-91. PubMed ID: 11896120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].
    Zhou ZW; Wang GQ; Wan DS; Pan ZZ; Li S; Chen G; Liao H
    Ai Zheng; 2004 Nov; 23(11 Suppl):1512-6. PubMed ID: 15566669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer.
    Ho DH; Covington W; Brown N; Lin SN; Pazdur R; Huo YY; Creaven PJ; Rustum YM; Meropol NJ; Lassere Y; Kuritani J; Hayakawa T
    Cancer Chemother Pharmacol; 2000; 46(5):351-6. PubMed ID: 11127938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.
    Ciccolini J; Mercier C; Blachon MF; Favre R; Durand A; Lacarelle B
    J Clin Pharm Ther; 2004 Aug; 29(4):307-15. PubMed ID: 15271097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil.
    Kato T; Shimamoto Y; Uchida J; Ohshimo H; Abe M; Shirasaka T; Fukushima M
    Anticancer Res; 2001; 21(3B):1705-12. PubMed ID: 11497250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Assay method for uracil, dihydrouracil, 5-fluorouracil and 5-fluoro-5, 6-dihydrouracil by high-performance liquid chromatography].
    Nakamura A; Kikuchi K; Ohishi T; Masuike T
    Gan To Kagaku Ryoho; 2004 Mar; 31(3):381-6. PubMed ID: 15045945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer.
    Heslin MJ; Yan J; Weiss H; Shao L; Owens J; Lucas VS; Diasio RB
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):399-404. PubMed ID: 12904894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronopharmacokinetics of oral tegafur and uracil in colorectal cancer patients.
    Etienne-Grimaldi MC; Cardot JM; François E; Renée N; Douillard JY; Gamelin E; Milano G
    Clin Pharmacol Ther; 2008 Mar; 83(3):413-5. PubMed ID: 17637782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of dihydropyrimidine dehydrogenase in cancer cells but not in stromal cells predicts the efficacy of fluorouracil treatment in patients with gastric carcinoma.
    Hisamitsu K; Tsujitani S; Yamaguchi K; Fukuda K; Konishi I; Kaibara N
    Anticancer Res; 2004; 24(4):2495-501. PubMed ID: 15330204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The serum and tissue concentrations of tegafur, 5-fluorouracil and uracil in patients with gastric and colorectal cancers after oral administration of UFT].
    Takahashi N; Nitta A; Saitou T; Mori Y; Kunii Y; Kikuchi K
    Gan To Kagaku Ryoho; 1988 Aug; 15(8):2319-23. PubMed ID: 3136701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.